CG
TXG icon

Cynosure Group’s 10x Genomics TXG Stock Holding History

Cynosure Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$546K Hold
25,730
– – 0.07% 76
2025
Q4 		$420K Hold
25,730
– – 0.04% 337
2025
Q3 		$301K Sell
25,730
-24
-0.1% -$313 0.03% 342
2025
Q2 		$298K Buy
25,754
+24
+0.1% +$219 0.03% 367
2025
Q1 		$225K Hold
25,730
– – 0.03% 369
2024
Q4 		$369K Sell
25,730
-15
-0.1% -$237 0.06% 161
2024
Q3 		$581K Buy
+25,745
New +$532K 0.08% 137

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cynosure Group's TXG Position: Q1 2026 in Review

Cynosure Group held its 10x Genomics (TXG) position steady in Q1 2026 at 25,730 shares worth $546K. The position accounts for 0.07% of the portfolio, ranked #76.

Cynosure Group first reported a position in TXG in Q3 2024 and has held it in 7 quarters since. The position peaked at $581K in Q3 2024. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Cynosure Group held 25,730 shares of 10x Genomics worth $546K as of Q1 2026.
  • Cynosure Group left its 10x Genomics share count unchanged in Q1 2026.
  • 10x Genomics made up 0.07% of Cynosure Group's portfolio in Q1 2026, its #76 holding.
  • Cynosure Group first reported a position in 10x Genomics in Q3 2024 and has held it in 7 quarters since.
  • Cynosure Group's 10x Genomics position peaked at $581K in Q3 2024.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.